{"denoms":[{"counts":[{"groupId":"BG000","value":"27"}],"units":"Participants"}],"groups":[{"description":"All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.\n\nPanobinostat, Lenalidomide and Dexamethasone: Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19. Lenalidomide will be given 25 mg: Days 1-21. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.","id":"BG000","title":"Panobinostat, Lenalidomide and Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"51","upperLimit":"75","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age >65 years","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"2"}],"description":"ECOG measures level of functioning in terms of daily living abilities:\n\n0 - Fully active, able to carry on all pre-disease performance without restriction\n\n1. \\- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. \\- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours","paramType":"COUNT_OF_PARTICIPANTS","title":"The Eastern Cooperative Oncology Group (ECOG) Performance","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"missing"}],"description":"The International Staging System (ISS) for Multiple Myeloma\n\nStage 1 ß2-M \\< 3.5 mg/dL and albumin =3.5 g/dL\n\nStage 2 Neither stage 1 nor stage 3\n\nStage 3 ß2-M ≥ 5.5 mg/L","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS Staging","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"IgG"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"IgA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"IgM"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"None"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Immunoglobulin subtype","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Any abnormality"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Any high risk abnormality"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"del(17p)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"chr1 amplification"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"t(4;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"del(13q)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"t(11;14)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"FISH","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.6","upperLimit":"12.4","value":"4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median time since diagnosis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"10","value":"3"}]}]}],"description":"Number of years participant was on any prior regimens","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior regimens","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"10","value":"3"}]}]}],"description":"The number of prior treatments the participants had received prior to baseline visit","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior therapy","unitOfMeasure":"regimens"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Dexamethasone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Thalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Lenalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Pomalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"Bortezomib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Carfilzomib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Autologous stem cell transplant"}],"description":"The number of participants that received any of the following chemo drugs","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Therapy, Exposed","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Dexamethasone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Thalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Lenalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Pomalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Bortezomib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Carfilzomib"}],"description":"The number of participants that received any of the following chemo drugs and relapsed from it.","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior therapy, Refractory","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"4","upperLimit":"20","value":"13"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median cumulative duration of prior lenalidomide (len) months","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"2","value":"1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior len regimens","unitOfMeasure":"regimens"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"25"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"15"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"10"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"5"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Not Len Refractory Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Doses of lenalidomide at time of PD on len","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Progressed while on last len regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Len in most recent prior regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Pom in most recent prior regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Dex in most recent prior regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Dex in last len-containing regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Minimal Response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Progressive disease"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Best response at last treatment","unitOfMeasure":"Participants"}],"populationDescription":"27 out of the 32 subjects are evaluable because the 5 patients either did not complete cycle 1, or enrolled but never dosed."}